Hi. I am
Dr David
Entrepreneur |
Biotech & Healthcare Superconnector |
Angel Investor (AKA Risk Taker) in Biotech & Healthcare
with a strong passion for fostering innovation, supporting early-stage ventures, and driving advancements in medical technology, life sciences, and healthcare solutions.
Current Positions
-
Founder, WT Health
-
Founder and Director of Strategic Partnerships, MedHouse
Education
-
Bachelor of Science (Double Major in Microbiology and Biochemistry), The University of Hong Kong
-
Bachelor of Medicine and Bachelor of Surgery, The Chinese University of Hong Kong
Deeply Understanding the Concept of Bootstrapping
Dr. David Lai founded WT Health in 2022, starting from a small clinic in a public housing estate. Drawing on his experience as a frontline doctor and his entrepreneurial spirit, he successfully transformed the company into a young and dynamic healthcare enterprise within just two years. Today, the company operates ten general practice and dental clinics, while also offering a range of medical services and courses.
Coming from a grassroots background and without financial backing from investors or partnerships, Dr. Lai has a deep understanding of the importance and core principles of bootstrapping for success. Despite operating in a traditional industry, he remains committed to innovating the business model. Through diligent planning and thoughtful risk-to-reward analysis, he has driven the rapid expansion of the company.
This impressive growth is no coincidence. It is built upon the foundation of an earlier initiative by Dr. Lai — MedHouse, a medical resource platform that connects over 2,600 doctors and medical students in Hong Kong. This platform not only supported the steady growth of WT Health’s traditional healthcare business but also created new opportunities for development and innovation.
Resources
A pool of doctors
including both General Practitioners and Specialists from public and private sectors, offering a wide range of information and expertise.
A strong network of key players and stakeholders
in the healthcare and biotechnology sectors, spanning both public and private domains.
A diverse range of capital sources
including contributions from doctors as well as individual investors, providing robust financial support and stability.
Investments
Dr. David Venture Makes Angel Investment in Illumos
Propel INSIHGT Precision Medicine Technology
Earlier this year, Dr David Venture provided angel funding to Illumos, an innovative tech company based in Hong Kong Science Park. This investment supports the development of their cutting-edge technology, INSIHGT (In Situ Host-Guest Chemistry for Three-dimensional Histology), which is poised to revolutionize precision medicine and medical research with its advanced multi-dimensional histological analysis capabilities, especially with clear potential to apply in immunochemical studies in oncological drug development and greatly improve patients’ treatment selection.
INSIHGT addresses the limitations of current tissue sample analysis technologies by significantly enhancing the accuracy and depth of tissue analysis. Through 3D tissue imaging, it offers a comprehensive understanding of tissue structures, both in morphological and immunochemical perspectives. It offers tissues with full penetration staining and antibodies binding. Compared to the significant sampling errors in 2D histology process that has been used for decades, it offers in a unbiased way to observe the true immunochemical interactions in tissue samples. This serves the fundamentals of precision medicine.
This technology has also attracted angel investment from Prof MOK Shu Kam, Tony, a globally recognized leader in precision oncology. His support not only affirms the innovative value of INSIHGT but also underscores its immense potential in advancing precision medicine. With these strategic investments, Illumos can further develop its 3D histology technology and enhance its biomarker analysis capabilities.
Dr LAI Cheuk Hei, David, founder of Dr David Venture, stated, "The success of INSIHGT reflects the dedication of the Illumos team and highlights Hong Kong's strength in healthcare and biotech innovation. We believe INSIHGT has the potential to set a new milestone in the global development of precision medicine."
Looking ahead, Dr David Venture plans to leverage its resources to promote the practical application of INSIHGT in pharmaceutical companies, universities and different verticals. medical institutions, accelerating its path to commercialization. They aim to explore its potential in cancer diagnosis, precision treatment, and other diseases, while supporting Hong Kong’s healthcare and biotech sectors through funding, networking, and market research to foster a vibrant innovation ecosystem.